LENVA 10 MG

A central point in the profile of Lenvatinib is the relationship between its molecular action and the cancer setting in which it is used. Inhibits VEGFR and additional receptor tyrosine kinases including FGFR. Its activity across vascular and other kinase pathways gives it a broader molecular footprint than a single-target inhibitor, helping explain its use across several tumor types. The record identifies it as VEGFR1-3/FGFR and other TKI within Targeted Therapy; VEGFR/Multikinase Inhibitor and lists Thyroid; RCC; Endometrial; HCC among the associated tumor types. The principal indications are Differentiated thyroid cancer; renal cell carcinoma; endometrial carcinoma; hepatocellular carcinoma in selected regions/settings. Regimen examples include Lenvatinib + pembrolizumab; lenvatinib + everolimus; lenvatinib monotherapy. The combination context matters: depending on the disease, the agent may be used alone or alongside other systemic treatments as specified in the database. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Any biomarker or disease-state requirement included in the indication should be considered when interpreting the entry. The same broad therapeutic class can contain medicines with different targets and therefore different clinical uses. This description intentionally remains descriptive rather than prescriptive, with no patient-specific dosing or treatment instructions. Current labels and applicable oncology guidelines should be consulted to confirm present-day indications and combinations.